A Mayo Clinic study tested metformin, believed to have anti-lymphoma activity, among patients with newly diagnosed diffuse large B-cell lymphoma or follicular lymphoma. (Source: CancerNetwork)
Tue Jun 25, 2019 06:00
A phase I/II trial tested the combination of niraparib and pembrolizumab in patients with recurrent ovarian carcinoma. (Source: CancerNetwork)
Tue Jun 25, 2019 06:00
A same-day biopsy program for women helped reduce disparities related to age, race, and insurance type in breast cancer care. (Source: CancerNetwork)
Tue Jun 25, 2019 06:00
A new trial investigated the efficacy of XELOX vs GEMOX as first-line therapy for advanced biliary tract cancers. (Source: CancerNetwork)
Tue Jun 25, 2019 06:00
The CALGB 50904 trial tested the addition of bortezomib to ofatumumab and bendamustine in patients with previously untreated high-risk follicular lymphoma. (Source: CancerNetwork)
Tue Jun 25, 2019 06:00
Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia. (Source: CancerNetwork)
Mon Jun 24, 2019 06:00
Researchers tested the MET inhibitor capmatinib in patients with non –small-cell lung cancer and a MET exon 14 skipping mutation. (Source: CancerNetwork)
Mon Jun 24, 2019 06:00
Many patients complain of " chemo brain, " or a drop in cognitive function during or after receiving chemotherapy, but there are strategies to manage chemo brain, as well as research on how chemotherapy affects the brain long-term. (Source: CancerNetwork)
Mon Jun 24, 2019 06:00
Researchers conducted a cost-effectiveness analysis on the two FDA-approved CAR T-cell therapies for diffuse large B-cell lymphoma. (Source: CancerNetwork)
Sun Jun 23, 2019 06:00
Lurbinectedin may represent a new treatment option as second-line therapy for patients with small-cell lung cancer. (Source: CancerNetwork)
Fri Jun 21, 2019 06:00
The gait speed of an older patient with a hematologic malignancy may be an indicator of that patient ’s frailty and could predict for worse clinical outcomes. (Source: CancerNetwork)
Thu Jun 20, 2019 06:00
Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide. (Source: CancerNetwork)
Thu Jun 20, 2019 06:00
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors. (Source: CancerNetwork)
Thu Jun 20, 2019 06:00
Researchers tested radiation therapy as a bridging therapy for patients with relapsed/refractory diffuse large B-cell lymphoma during the interval between T-cell collection and final CAR T administration. (Source: CancerNetwork)
Thu Jun 20, 2019 06:00
In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
Dr. Makker summarizes the standard of care for the treatment of advanced endometrial cancer, with a look forward to the multitude of clinical trials evaluating novel therapy combinations that are currently enrolling patients or underway. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
A study in the Journal of the National Cancer Institute evaluated responses in men vs women to combination chemotherapy and a PD-1 or PD-L1 inhibitor. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
Findings on the efficacy of the RET inhibitor BLU-667 in RET-altered medullary thyroid cancer and papillary thyroid cancer patients was presented at ASCO 2019. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
In this article, we provide a case-based expert opinion on the duration of extended adjuvant endocrine therapy, use of biomarkers in guiding this decision, and toxicities to be considered when recommending this treatment. (Source: CancerNetwork)
Wed Jun 19, 2019 06:00
The FDA approved pembrolizumab as a treatment option for patients with metastatic small-cell lung cancer. (Source: CancerNetwork)
Tue Jun 18, 2019 06:00
A study in JAMA Oncology evaluated re-administration of immune checkpoint blockade in cancer patients who experienced a grade 2 or higher immune-related adverse event. (Source: CancerNetwork)
Tue Jun 18, 2019 06:00
How much do you know about the incidence of extramedullary disease in patients with multiple myeloma? Take our latest quiz to test your knowledge. (Source: CancerNetwork)
Tue Jun 18, 2019 06:00
Despite better detection, the incidence of pediatric thyroid cancer increased by 9.5% per year from 2006 to 2013 compared with 1.1% per year from 1973 to 2006. (Source: CancerNetwork)
Tue Jun 18, 2019 06:00
Late relapses occurred more commonly among patients with DLBCL with concurrent indolent lymphoma at initial diagnosis and those with GCB subtype. (Source: CancerNetwork)
Tue Jun 18, 2019 06:00
A meta-analysis on existing data on the use of autologous stem cell transplant in older patients with newly diagnosed multiple myeloma confirmed the need for randomized controlled trials. (Source: CancerNetwork)
Tue Jun 18, 2019 06:00
Baseline left ventricular diastolic dysfunction may help predict the incidence of severe carfilzomib-induced cardiovascular adverse events in patients with multiple myeloma. (Source: CancerNetwork)
Mon Jun 17, 2019 06:00
An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Mon Jun 17, 2019 06:00
This slideshow reviews the latest guidelines and updates on colorectal cancer screening. (Source: CancerNetwork)
Mon Jun 17, 2019 06:00
How much do you know about the link between various germline mutations and ovarian cancer? Take our latest quiz to test your knowledge. (Source: CancerNetwork)
Mon Jun 17, 2019 06:00
Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Mon Jun 17, 2019 06:00
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer. (Source: CancerNetwork)
Fri Jun 14, 2019 06:00
Early data on the safety and tolerability of combination venetoclax and cytarabine or cytarabine/idarubicin were presented at ASCO 2019. (Source: CancerNetwork)
Fri Jun 14, 2019 06:00
Research evaluated whether initiating breast cancer screening at age 30 may be preferable to current guidelines among survivors of childhood cancer with a history of chest irradiation. (Source: CancerNetwork)
Fri Jun 14, 2019 06:00
A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia. (Source: CancerNetwork)
Fri Jun 14, 2019 06:00
Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
The PAIREDCAP trial looked at different biopsy approaches to see which has the highest cancer detection rate for prostate cancer. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
This phase III trial tested T-DM1 plus pertuzumab vs chemotherapy and dual HER2 blockade in patients with HER2+ breast cancer. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
The results of the first randomized clinical trial evaluating the link between a low-fat diet and breast cancer incidence and mortality were presented at ASCO 2019. (Source: CancerNetwork)
Thu Jun 13, 2019 06:00
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for mCRPC. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
The FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
Researchers looked at patient-reported outcomes with partial breast vs whole breast irradiation in patients with breast cancer who were not receiving chemotherapy. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
The GIM4 study looked at the effect of 2 to 3 years vs 5 years of letrozole on risk of recurrence in HR-positive early breast cancer. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
An analysis of the phase III SOLO1 trial examined safety signals with olaparib maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
Cancer Network spoke with Anna F. Farago, MD, medical oncologist at Massachusetts General, about recent research presented at ASCO 2019 on the efficacy of new cytotoxic strategies compared with chemotherapy for the treatment of relapsed small-cell lung cancer patients. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer. (Source: CancerNetwork)
Wed Jun 12, 2019 06:00
Researchers analyzed recurrence and survival outcomes for clear cell ovarian carcinoma in the JGOG3017/GCIG trial. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Mehmet Sitki Copur, MD, of Morrison Cancer Center, about his work in multiplex genomic testing as part of a 4-year experience in 2 community practices in central rural Nebraska. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Taofeek Kunle Owonikoko, MD, PhD, of Emory University, about talazoparib for patients with HRRD-positive stage IV squamous cell lung cancer. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology. (Source: CancerNetwork)
Tue Jun 11, 2019 06:00
Researchers tested simultaneous vs delayed rituximab with cladribine in patients with hairy cell leukemia. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Findings from a pooled analysis of two phase III trials, COMBI-d and COMBI-v, centered on outcomes with first-line dabrafenib plus trametinib vs either agent alone. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
In this randomized phase III trial, researchers compared cytoreductive nephrectomy vs sunitinib alone in patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer who experienced response to platinum-based chemotherapy. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Pembrolizumab plus axitinib significantly improved overall survival, progression-free survival, and response rate as first-line treatment compared with sunitinib in patients with metastatic renal cell carcinoma (RCC) with intermediate/poor risk disease and those with sarcomatoid features, according to results of the KEYNOTE-426 study (abstract 4500) presented at the 2019 American Society of Clinical Oncology (ASCO) (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Cancer Network spoke with Steven H. Lin, MD, PhD, of MD Anderson Cancer Center, on the findings of a phase II trial of atezolizumab plus chemoradiation therapy in locally advanced non-small-cell lung cancer. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Cancer Network spoke with Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, on how ribociclib plus hormone therapy extends survival for patients with premenopausal advanced HR-positive breast cancer. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Cancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
The results of the phase II trial examining combination immunotherapy were presented during the ASCO 2019 meeting. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Cancer Network spoke with Daniel McFarland, DO, of Memorial Sloan Kettering Cancer Center, about building programs to prevent burnout and suicide in oncology providers. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Cancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Cancer Network spoke with Patricia Eifel, MD, of the University of Texas MD Anderson Cancer Center, about the current shifts in the treatment of cervical cancer. (Source: CancerNetwork)
Mon Jun 10, 2019 06:00
Data from the largest randomized neoadjuvant trial in resectable stage IIIB–IVM1a melanoma to date were presented at ASCO 2019. (Source: CancerNetwork)
Fri Jun 07, 2019 06:00
Maintenance rituximab was tested in patients with diffuse large B-cell lymphoma who achieved complete remission after R-CHOP. (Source: CancerNetwork)
Fri Jun 07, 2019 06:00
In this video, Dr. McFarland of Memorial Sloan-Kettering Cancer Center spoke with Cancer Network at ASCO 2019 about depression in lung cancer and dopamine as potential therapy. (Source: CancerNetwork)
Fri Jun 07, 2019 06:00
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope at ASCO 2019 about data on emerging MET inhibitors in the treatment of lung cancer patients. (Source: CancerNetwork)
Fri Jun 07, 2019 06:00
Cancer Network spoke with Tina Cascone, MD, of MD Anderson Cancer Center, at ASCO 2019 about combination checkpoint blockade in the pre-surgical setting for early-stage NSCLC. (Source: CancerNetwork)
Fri Jun 07, 2019 06:00
Cancer Network spoke with Nathan A. Pennell, MD, PhD, of Cleveland Clinic at ASCO 2019 regarding current use of and barriers to molecular testing in NSCLC. (Source: CancerNetwork)
Fri Jun 07, 2019 06:00
The investigators looked at whether whole-brain radiotherapy improved outcomes in patients with melanoma brain metastasis. (Source: CancerNetwork)
Fri Jun 07, 2019 06:00
Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Thu Jun 06, 2019 06:00
The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Thu Jun 06, 2019 06:00
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation. (Source: CancerNetwork)
Thu Jun 06, 2019 06:00
Researchers tested the administration of bone-targeted agents once every 12 weeks vs once every 4 weeks for a year in patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Thu Jun 06, 2019 06:00
Updated results from ENESTop show patients with CML remain in treatment-free remission after stopping nilotinib. (Source: CancerNetwork)
Thu Jun 06, 2019 06:00
A phase III study comparing the efficacy and safety of nivolumab plus an experimental interleukin-2 –based drug vs nivolumab alone in patients with metastatic melanoma is now enrolling patients. (Source: CancerNetwork)
Wed Jun 05, 2019 06:00
This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer. (Source: CancerNetwork)
Wed Jun 05, 2019 06:00
Researchers tested treatment with bone-protecting agents in men with metastatic castration-resistant prostate cancer treated with enzalutamide or radium-223. (Source: CancerNetwork)
Wed Jun 05, 2019 06:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου